We provide you with 20 years of free, institutional-grade data for ALLO stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of ALLO. Explore the full financial landscape of ALLO stock.
| Reported Date | CIK | Ticker | Type | |
|---|---|---|---|---|
| 2025-08-13 | 1737287 | ALLO | 10-Q | Url |
| 2025-05-13 | 1737287 | ALLO | 10-Q | Url |
| 2025-03-13 | 1737287 | ALLO | 10-K | Url |
| 2024-11-07 | 1737287 | ALLO | 10-Q | Url |
| 2024-08-07 | 1737287 | ALLO | 10-Q | Url |
| 2024-05-13 | 1737287 | ALLO | 10-Q | Url |
| 2024-03-14 | 1737287 | ALLO | 10-K | Url |
| 2023-11-02 | 1737287 | ALLO | 10-Q | Url |
| 2023-08-02 | 1737287 | ALLO | 10-Q | Url |
| 2023-05-03 | 1737287 | ALLO | 10-Q | Url |
| 2023-02-28 | 1737287 | ALLO | 10-K | Url |
| 2022-11-02 | 1737287 | ALLO | 10-Q | Url |
| 2022-08-09 | 1737287 | ALLO | 10-Q | Url |
| 2022-05-04 | 1737287 | ALLO | 10-Q | Url |
| 2022-02-23 | 1737287 | ALLO | 10-K | Url |
| 2021-11-04 | 1737287 | ALLO | 10-Q | Url |
| 2021-08-04 | 1737287 | ALLO | 10-Q | Url |
| 2021-05-05 | 1737287 | ALLO | 10-Q | Url |
| 2021-02-25 | 1737287 | ALLO | 10-K | Url |
| 2020-11-04 | 1737287 | ALLO | 10-Q | Url |
| 2020-08-05 | 1737287 | ALLO | 10-Q | Url |
| 2020-05-06 | 1737287 | ALLO | 10-Q | Url |
| 2020-02-27 | 1737287 | ALLO | 10-K | Url |
| 2019-11-05 | 1737287 | ALLO | 10-Q | Url |
| 2019-08-07 | 1737287 | ALLO | 10-Q | Url |
| 2019-05-07 | 1737287 | ALLO | 10-Q | Url |
| 2019-03-08 | 1737287 | ALLO | 10-K | Url |
| 2018-11-21 | 1737287 | ALLO | 10-Q | Url |
| 2018-09-14 | 1737287 | ALLO | S-1 | Url |
Allogene Therapeutics, Inc(NASDAQ:ALLO) 
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candi...
Website: http://www.allogene.com
Founded: 2017
Full Time Employees: 264
Sector: Healthcare
Industry: Biotechnology
The information provided in this report about ALLO stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.